HER 2 LOW-EXPRESSING BREAST CANCER
Clinical trials for HER 2 LOW-EXPRESSING BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 LOW-EXPRESSING BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 LOW-EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo strategy takes on Hard-to-Treat breast cancer
Disease control Not yet recruitingThis phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low triple-negative breast cancer that has spread. About 260 participants will be randomly assigned to receive either the altern…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 26, 2026 13:20 UTC
-
Can a smarter scan spot breast cancer treatment failure faster?
Knowledge-focused Not yet recruitingThis study compares two types of scans—standard CT and bone scans versus PET-CT—to see which better evaluates how well the drug trastuzumab deruxtecan (T-DXd) works in people with HER2 low metastatic breast cancer. About 262 participants will be split into two groups and scanned …
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:12 UTC